Product Information
Registration Status: ActiveSIN09695P
TERRAMYCIN OPHTHALMIC OINTMENT is approved to be sold in Singapore with effective from 1998-06-04. It is marketed by PFIZER PTE LTD, with the registration number of SIN09695P.
This product contains Oxytetracycline 5mg/g, and Polymyxin B 10000 iu/g in the form of OINTMENT. It is approved for OPHTHALMIC use.
This product is manufactured by PT PFIZER INDONESIA in INDONESIA REP OF.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Product Reference
Important Note: For generic product, the SPC/PIL provided may not be brand specific.
{{/items}} {{^items}}Description
A tetracycline analog isolated from the actinomycete streptomyces rimosus and used in a wide variety of clinical conditions.
Indication
Oxytetracycline is indicated for treatment of infections caused by a variety of Gram positive and Gram negative microorganisms including Mycoplasma pneumoniae, Pasteurella pestis, Escherichia coli, Haemophilus influenzae (respiratory infections), and Diplococcus pneumoniae.
Mechanism of Action
Oxytetracycline inhibits cell growth by inhibiting translation. It binds to the 30S ribosomal subunit and prevents the amino-acyl tRNA from binding to the A site of the ribosome. The binding is reversible in nature. Oxytetracycline is lipophilic and can easily pass through the cell membrane or passively diffuses through porin channels in the bacterial membrane.
Pharmacokinetics
- Absorption
- Readily absorbed following oral administration.
- Distribution
- Metabolism
- Elimination
Toxicity
Adverse effects may include stomach or bowel upsets and rarely allergic reactions. Very rarely severe headache and vision problems may be signs of dangerous intracranial hypertenion.
Active Ingredient/Synonyms
5-Hydroxytetracycline | Embryostat | Hydroxytetracyclinum | Mepatar | Oxitetraciclina | Oxyterracin | Oxyterracine | Oxytetracyclin | Oxytétracycline | Oxytetracycline (anhydrous) | Oxytetracycline amphoteric | Oxytetracyclinum | Oxytetracycline |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.
Description
Polymyxin B sulfate is a mixture of polymyxins B1 and B2, obtained from Bacillus polymyxa strains. They are basic polypeptides of about eight amino acids and have cationic detergent action on cell membranes. Polymyxin B is used for infections with gram-negative organisms, but may be neurotoxic and nephrotoxic. All gram-positive bacteria, fungi, and the gram-negative cocci, N. gonorrhea and N. menigitidis, are resistant. It is appropriate for treatment of infections of the urinary tract, meninges, and blood stream, caused by susceptible strains of Pseudomonas aeruginosa.
Indication
For treatment of infections of the urinary tract, meninges, and blood stream, caused by susceptible strains of Pseudomonas aeruginosa.
Mechanism of Action
Polymyxin B sulfate has a bactericidal action against almost all gram-negative bacilli except the Proteus group. Polymyxin B sulfate interacts with the lipopolysaccharide of the cytoplasmic outer membrane of Gram-negative bacteria, altering membrane permeability and causing cell death. It does not need to enter the cell.
Pharmacokinetics
- Absorption
- Not absorbed from the normal alimentary tract.
- Distribution
- Metabolism
- Elimination
Toxicity
Overdose can cause stomach pains, vomiting, and diarrhea.
Active Ingredient/Synonyms
Polimixina B | Polymyxin B | Polymyxin B Sulphate | Polymyxin-B-Sulfat | Polymyxine B | Polymyxine B (sulfate de) | Polymyxini B sulfas | Polymyxinum B | Polymyxin B Sulfate |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.